Telratolimod

Telratolimod is an agonist of toll-like receptor 7 (TLR7) and TLR8. It increases the production of IL-8 in HEK293 cells expressing human TLR7 or TLR8 and increases protein levels of IFN-alpha and TNF-alpha in isolated human peripheral blood mononuclear cells (PBMCs). Telratolimod (1 mg/kg) increases the HA-induced secretion of IFN-gamma in mouse splenocytes ex vivo but does not induce the production of TNF-alpha in mouse serum in vivo. Telratolimod nanoparticles, when used as an adjuvant with the HIV-1 envelope glycoprotein, enhance neutralizing antibody responses to an HIV-1 pseudovirus in rhesus macaques for at least one year. Intratumoral administration of telratolimod reduces tumor growth and increases metastasis-free survival in E0771 and 4T1.2 murine mammary carcinoma models and increases intratumoral production of cytokines in a 4T1.2 murine model, an effect that is enhanced by coadministration of anti-PD-1 antibodies.Formal Name: N-[4-[(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy]butyl]-octadecanamide. CAS Number: 1359993-59-1. Synonyms: MEDI9197, 3M-052. Molecular Formula: C36H59N5O2. Formula Weight: 593.9. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: slightly soluble, Ethanol: slightly soluble. lambdamax: 248 nm. SMILES: O=C(CCCCCCCCCCCCCCCCC)NCCCCON1C(CCCC)=NC2=C1C3=C(C=CC=C3)N=C2N. InChi Code: InChI=1S/C36H59N5O2/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-18-19-27-33(42)38-28-22-23-29-43-41-32(26-6-4-2)40-34-35(41)30-24-20-21-25-31(30)39-36(34)37/h20-21,24-25H,3-19,22-23,26-29H2,1-2H3,(H2,37,39)(H,38,42). InChi Key: RRTPWQXEERTRRK-UHFFFAOYSA-N.